Compounds > n-acetyltalosaminuronic acid
Page last updated: 2024-09-04

n-acetyltalosaminuronic acid and Multiple Sclerosis, Relapsing-Remitting

n-acetyltalosaminuronic acid has been researched along with Multiple Sclerosis, Relapsing-Remitting in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Bava, CI; Bertolotto, A; Capobianco, MA; Malucchi, S; Martire, S; Valentino, P1

Other Studies

1 other study(ies) available for n-acetyltalosaminuronic acid and Multiple Sclerosis, Relapsing-Remitting

ArticleYear
sNFL applicability as additional monitoring tool in natalizumab extended interval dosing regimen for RRMS patients.
    Multiple sclerosis and related disorders, 2022, Volume: 67

    Topics: Adolescent; Adult; Biomarkers; Humans; Leukoencephalopathy, Progressive Multifocal; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Young Adult

2022